Regeneron Schedules November 22, 2010 Teleconference and Webcast to Discuss Results of Two Phase 3 Studies with VEGF Trap-Eye in Wet Age-related Macular Degeneration

TARRYTOWN, N.Y.,Nov. 19, 2010/PRNewswire-FirstCall/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq:REGN) today announced that it will hold a teleconference and webcast at8:30 a.m. Eastern TimeonMonday, November 22, to discuss results of two Phase 3 studies with VEGF Trap-Eye in Wet Age-related Macular Degeneration, VIEW 1 and VIEW 2, and its VEGF Trap-Eye program.  A press release will be issued on Monday prior to the call.

To participate in the live call onMonday, November 22, at8:30 a.m. Eastern Time, please dial (877) 390-5538 for domestic callers and (408) 940-3843 for international callers, participant code 27197068.  The live conference call is being webcast and it can be accessed on the "Newsroom" page of the Company's web site,www.regeneron.com.  The webcast will be available for 30 days following the call.

Regeneron is a fully integrated biopharmaceutical company that discovers, develops, and commercializes medicines for the treatment of serious medical conditions.  In addition to ARCALYST® (rilonacept) Injection for Subcutaneous Use, its first commercialized product, Regeneron has therapeutic candidates in Phase 3 clinical trials for the potential treatment of gout, diseases of the eye (wet age-related macular degeneration and central retinal vein occlusion), and certain cancers.  Additional therapeutic candidates developed from proprietary Regeneron technologies for creating fully human monoclonal antibodies are in earlier stage development programs in rheumatoid arthritis and other inflammatory conditions, pain, cholesterol reduction, allergic and immune conditions, and cancer.  Additional information about Regeneron and recent news releases are available on Regeneron's web site atwww.regeneron.com.